Skip to main content
SpringerLink
Log in

Epigenetics in Personalized Management of Lung Cancer

  • Chapter
  • First Online:
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 890))

Abstract

In last several years, the focus on the origin and progression of human cancers has shifted from genetic to epigenetic regulation, with particular attention to methylation and acetylation events that have profound effect on the eventual expression of oncogenes and the suppression of tumor suppressors. A few drugs targeting these epigenetic changes have already been approved for treatment, albeit not for lung cancer. With the recent advances in the push towards personalized therapy, questions have been asked about the possible targeting of epigenetic events for personalized lung cancer therapy. Some progress has been made but a lot needs to be done. In this chapter, a succinct review of these topics is provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29

    Article  PubMed  Google Scholar 

  2. Arcaro A (2015) Targeted therapies for small cell lung cancer: where do we stand? Crit Rev Oncol Hematol 95:133–264

    Article  Google Scholar 

  3. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358(11):1148–1159

    Article  PubMed  CAS  Google Scholar 

  4. Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895):89–92

    Article  PubMed  CAS  Google Scholar 

  5. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW et al (1983) The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 11(19):6883–6894

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ (2014) Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 14(6):395–405

    Article  PubMed  CAS  Google Scholar 

  7. Choi JD, Lee JS (2013) Interplay between epigenetics and genetics in cancer. Genomics Inform 11(4):164–173

    Article  PubMed  PubMed Central  Google Scholar 

  8. Campbell RM, Tummino PJ (2014) Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest 124(1):64–69

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Heyn H, Esteller M (2012) DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 13(10):679–692

    Article  PubMed  CAS  Google Scholar 

  10. Li J, Jin H, Wang X (2014) Epigenetic biomarkers: potential applications in gastrointestinal cancers. ISRN Gastroenterol 2014:464015

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Shukla S, Meeran SM (2014) Epigenetics of cancer stem cells: pathways and therapeutics. Biochim Biophys Acta 1840(12):3494–3502

    Article  PubMed  CAS  Google Scholar 

  12. Ohnishi K, Semi K, Yamada Y (2014) Epigenetic regulation leading to induced pluripotency drives cancer development in vivo. Biochem Biophys Res Commun 455:10–15

    Article  PubMed  CAS  Google Scholar 

  13. Easwaran H, Tsai HC, Baylin SB (2014) Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 54(5):716–727

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Tam WL, Weinberg RA (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19(11):1438–1449

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Wang Y, Shang Y (2013) Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Exp Cell Res 319(2):160–169

    Article  PubMed  CAS  Google Scholar 

  16. Liu X, Chen X, Yu X, Tao Y, Bode AM, Dong Z et al (2013) Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res 32:96

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Baer C, Claus R, Plass C (2013) Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res 73(2):473–477

    Article  PubMed  CAS  Google Scholar 

  18. Ahmad A, Li Y, Bao B, Kong D, Sarkar FH (2014) Epigenetic regulation of miRNA-cancer stem cells nexus by nutraceuticals. Mol Nutr Food Res 58(1):79–86

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Miceli M, Bontempo P, Nebbioso A, Altucci L (2014) Natural compounds in epigenetics: a current view. Food Chem Toxicol 73c:71–83

    Article  CAS  Google Scholar 

  20. Langevin SM, Kratzke RA, Kelsey KT (2014) Epigenetics of lung cancer. Transl Res 165:74–90

    Article  PubMed  CAS  Google Scholar 

  21. Jakopovic M, Thomas A, Balasubramaniam S, Schrump D, Giaccone G, Bates SE (2013) Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front Oncol 3:261

    Article  PubMed  PubMed Central  Google Scholar 

  22. Vandermeers F, Neelature Sriramareddy S, Costa C, Hubaux R, Cosse JP, Willems L (2013) The role of epigenetics in malignant pleural mesothelioma. Lung Cancer 81(3):311–318

    Article  PubMed  Google Scholar 

  23. Balgkouranidou I, Liloglou T, Lianidou ES (2013) Lung cancer epigenetics: emerging biomarkers. Biomark Med 7(1):49–58

    Article  PubMed  CAS  Google Scholar 

  24. Okayama H, Schetter AJ, Ishigame T, Robles A, Kohno T, Yokota J et al (2014) The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts. Cancer Epidemiol Biomarkers Prev 23:2884–2894

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Akagi I, Okayama H, Schetter AJ, Robles AI, Kohno T, Bowman ED et al (2013) Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. Cancer Res 73(13):3821–3832

    Article  PubMed  CAS  Google Scholar 

  26. Ruiz R, Raez LE, Rolfo C (2015) Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs 24:1101–1109

    Article  PubMed  CAS  Google Scholar 

  27. Falkenberg KJ, Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13(9):673–691

    Article  PubMed  CAS  Google Scholar 

  28. Heerboth S, Lapinska K, Snyder N, Leary M, Rollinson S, Sarkar S (2014) Use of epigenetic drugs in disease: an overview. Genet Epigenet 6:9–19

    PubMed  PubMed Central  CAS  Google Scholar 

  29. Mottamal M, Zheng S, Huang TL, Wang G (2015) Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20(3):3898–3941

    Article  PubMed  CAS  Google Scholar 

  30. Dekker FJ, Haisma HJ (2009) Histone acetyl transferases as emerging drug targets. Drug Discov Today 14(19–20):942–948

    Article  PubMed  CAS  Google Scholar 

  31. Manzo F, Tambaro FP, Mai A, Altucci L (2009) Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Pat 19(6):761–774

    Article  PubMed  CAS  Google Scholar 

  32. Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H (2007) The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res 142(2):219–226

    Article  PubMed  CAS  Google Scholar 

  33. Chun SM, Lee JY, Choi J, Lee JH, Hwang JJ, Kim CS et al (2015) Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One 10(3), e0119379

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Kong D, Ahmad A, Bao B, Li Y, Banerjee S, Sarkar FH (2012) Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One 7(9), e45045

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Miozzo M, Vaira V, Sirchia SM (2015) Epigenetic alterations in cancer and personalized cancer treatment. Future Oncol 11(2):333–348

    Article  PubMed  CAS  Google Scholar 

  36. Shukla S, Khan S, Kumar S, Sinha S, Farhan M, Bora HK et al (2015) Cucurbitacin B alters the expression of tumor-related genes by epigenetic modifications in NSCLC and inhibits NNK-induced lung tumorigenesis. Cancer Prev Res (Phila) 8(6):552–562

    Article  CAS  Google Scholar 

  37. Tang J, Xiong Y, Zhou HH, Chen XP (2014) DNA methylation and personalized medicine. J Clin Pharm Ther 39(6):621–627

    Article  PubMed  CAS  Google Scholar 

  38. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M (2006) DNA methylation: bisulphite modification and analysis. Nat Protoc 1(5):2353–2364

    Article  PubMed  CAS  Google Scholar 

  39. Li J, Ching T, Huang S, Garmire LX (2015) Using epigenomics data to predict gene expression in lung cancer. BMC Bioinf 16(suppl 5):S10

    Article  Google Scholar 

  40. Kim Y, Kim DH (2015) CpG island hypermethylation as a biomarker for the early detection of lung cancer. Methods Mol Biol 1238:141–171

    Article  PubMed  Google Scholar 

  41. Khakpour G, Pooladi A, Izadi P, Noruzinia M, Tavakkoly Bazzaz J (2015) DNA methylation as a promising landscape: a simple blood test for breast cancer prediction. Tumour Biol 36:4905–4912

    Article  PubMed  CAS  Google Scholar 

  42. Volkel P, Dupret B, Le Bourhis X, Angrand PO (2015) Diverse involvement of EZH2 in cancer epigenetics. Am J Transl Res 7(2):175–193

    PubMed  PubMed Central  Google Scholar 

  43. McCabe MT, Creasy CL (2014) EZH2 as a potential target in cancer therapy. Epigenomics 6(3):341–351

    Article  PubMed  CAS  Google Scholar 

  44. Kondo Y (2014) Targeting histone methyltransferase EZH2 as cancer treatment. J Biochem 156(5):249–257

    Article  PubMed  Google Scholar 

  45. Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L et al (2012) Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 7(3), e33729

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ et al (2015) EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 520(7546):239–242

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Wu PC, Lu JW, Yang JY, Lin IH, Ou DL, Lin YH et al (2014) H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis. Cancer Res 74(24):7333–7343

    Article  PubMed  CAS  Google Scholar 

  48. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al (2007) High-resolution profiling of histone methylations in the human genome. Cell 129(4):823–837

    Article  PubMed  CAS  Google Scholar 

  49. Falahi F, Sgro A, Blancafort P (2015) Epigenome engineering in cancer: fairytale or a realistic path to the clinic? Front Oncol 5:22

    Article  PubMed  PubMed Central  Google Scholar 

  50. Dai SP, Xie C, Ding N, Zhang YJ, Han L, Han YW (2015) Targeted inhibition of genome-wide DNA methylation analysis in epigenetically modulated phenotypes in lung cancer. Med Oncol 32(6):615

    Article  PubMed  CAS  Google Scholar 

  51. Bulk E, Ay AS, Hammadi M, Ouadid-Ahidouch H, Schelhaas S, Hascher A et al (2015) Epigenetic dysregulation of K 3.1 channels induces poor prognosis in lung cancer. Int J Cancer 137:1306–1317

    Article  PubMed  CAS  Google Scholar 

  52. Mansfield AS, Wang L, Cunningham JM, Jen J, Kolbert CP, Sun Z et al (2015) DNA methylation and RNA expression profiles in lung adenocarcinomas of never-smokers. Cancer Genet 208(5):253–260

    Article  PubMed  CAS  Google Scholar 

  53. Soes S, Daugaard IL, Sorensen BS, Carus A, Mattheisen M, Alsner J et al (2014) Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. Oncoscience 1(5):367–374

    Article  PubMed  PubMed Central  Google Scholar 

  54. Barrow TM, Michels KB (2014) Epigenetic epidemiology of cancer. Biochem Biophys Res Commun 455:70–83

    Article  PubMed  CAS  Google Scholar 

  55. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K et al (2006) Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66(6):3338–3344

    Article  PubMed  CAS  Google Scholar 

  56. Cirincione R, Lintas C, Conte D, Mariani L, Roz L, Vignola AM et al (2006) Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Int J Cancer 118(5):1248–1253

    Article  PubMed  CAS  Google Scholar 

  57. Lou-Qian Z, Rong Y, Ming L, Xin Y, Feng J, Lin X (2013) The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis. PLoS One 8(1), e54970

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Miao Y, Wang L, Zhang X, Xu X, Jiang G, Fan C et al (2014) Promoter methylation-mediated silencing of beta-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis. PLoS One 9(11), e112258

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Xue R, Yang C, Zhao F, Li D (2014) Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC. Onco Targets Ther 7:1987–1996

    PubMed  PubMed Central  CAS  Google Scholar 

  60. Shi M, Wang S, Yao Y, Li Y, Zhang H, Han F et al (2014) Biological and clinical significance of epigenetic silencing of MARVELD1 gene in lung cancer. Sci Rep 4:7545

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Liu WB, Han F, Jiang X, Chen HQ, Zhao H, Liu Y et al (2015) TMEM196 acts as a novel functional tumour suppressor inactivated by DNA methylation and is a potential prognostic biomarker in lung cancer. Oncotarget 6:21225–21239

    Article  PubMed  PubMed Central  Google Scholar 

  62. Rhee YY, Lee TH, Song YS, Wen X, Kim H, Jheon S et al (2015) Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma. Virchows Arch 466(6):675–683

    Article  PubMed  CAS  Google Scholar 

  63. Zhou C, Qin Y, Xie Z, Zhang J, Yang M, Li S et al (2015) NPTX1 is a novel epigenetic regulation gene and associated with prognosis in lung cancer. Biochem Biophys Res Commun 458(2):381–386

    Article  PubMed  CAS  Google Scholar 

  64. Li N, Li S (2015) Epigenetic inactivation of SOX1 promotes cell migration in lung cancer. Tumour Biol 36:4603–4610

    Article  PubMed  CAS  Google Scholar 

  65. Li W, Deng J, Wang SS, Ma L, Pei J, Zeng XX et al (2014) Association of methylation of the RAR-beta gene with cigarette smoking in non-small cell lung cancer with Southern-Central Chinese population. Asian Pac J Cancer Prev 15(24):10937–10941

    Article  PubMed  Google Scholar 

  66. Avila-Moreno F, Armas-Lopez L, Alvarez-Moran AM, Lopez-Bujanda Z, Ortiz-Quintero B, Hidalgo-Miranda A et al (2014) Overexpression of MEOX2 and TWIST1 is associated with H3K27me3 levels and determines lung cancer chemoresistance and prognosis. PLoS One 9(12), e114104

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Zuco V, Cassinelli G, Cossa G, Gatti L, Favini E, Tortoreto M et al (2015) Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor. Biochem Pharmacol 94(2):79–90

    Article  PubMed  CAS  Google Scholar 

  68. El-Awady RA, Herzi F, Al-Tunaiji H, Saleh EM, Abdel-Wahab AH, Al Homssi A et al (2015) Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy. Cancer Biol Ther 16:1056–1070

    Article  PubMed  CAS  Google Scholar 

  69. Tao L, Huang G, Chen Y, Chen L (2015) DNA methylation of DKK3 modulates docetaxel chemoresistance in human nonsmall cell lung cancer cell. Cancer Biother Radiopharm 30(2):100–106

    Article  PubMed  CAS  Google Scholar 

  70. Vendetti FP, Topper M, Huang P, Dobromilskaya I, Easwaran H, Wrangle J et al (2015) Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget 6(1):56–70

    Article  PubMed  PubMed Central  Google Scholar 

  71. Shenker NS, Polidoro S, van Veldhoven K, Sacerdote C, Ricceri F, Birrell MA et al (2013) Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet 22(5):843–851

    Article  PubMed  CAS  Google Scholar 

  72. Shenker NS, Ueland PM, Polidoro S, van Veldhoven K, Ricceri F, Brown R et al (2013) DNA methylation as a long-term biomarker of exposure to tobacco smoke. Epidemiology 24(5):712–716

    Article  PubMed  Google Scholar 

  73. Baccarelli A, Wright RO, Bollati V, Tarantini L, Litonjua AA, Suh HH et al (2009) Rapid DNA methylation changes after exposure to traffic particles. Am J Respir Crit Care Med 179(7):572–578

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Belinsky SA (2015) Unmasking the lung cancer epigenome. Annu Rev Physiol 77:453–474

    Article  PubMed  CAS  Google Scholar 

  75. Hamm CA, Costa FF (2015) Epigenomes as therapeutic targets. Pharmacol Ther 151:72–86

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Karmanos Cancer Institute, Wayne State University, Detroit, MI, 48201, USA

    Aamir Ahmad

Authors
  1. Aamir Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aamir Ahmad .

Editor information

Editors and Affiliations

  1. Wayne State University, Karmanos Cancer Institute, Detroit, Michigan, USA

    Aamir Ahmad

  2. Karamanos Cancer Institute, Wayne State University, Detroit, Michigan, USA

    Shirish M. Gadgeel

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ahmad, A. (2016). Epigenetics in Personalized Management of Lung Cancer. In: Ahmad, A., Gadgeel, S. (eds) Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. Advances in Experimental Medicine and Biology, vol 890. Springer, Cham. https://doi.org/10.1007/978-3-319-24932-2_6

Download citation

Publish with us

Policies and ethics

Search

Navigation